Lol!
Of course WARMTH isn't our study, that's why it's called an INDEPENDANT trial.
Of course studies can be compared. Some studies ARE comparisons of other studies (meta analyses for example).
In this case, we can't make any claims, but it is worth a PS announcement simply because of the huge difference in patient outcomes between the two studies with similar patient selection criteria. Very promising. We'll soon find out if Vision achieves a similar result to WARMTH.
Ann: New Independent Trial Data Supports Potential of Veyonda, page-9
-
- There are more pages in this discussion • 33 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
0.010(10.0%) |
Mkt cap ! $32.14M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 11.5¢ | 10.5¢ | $19.51K | 177.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 45861 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.5¢ | 10000 | 1 |
View Market Depth
| Last trade - 15.41pm 18/09/2024 (20 minute delay) ? |
| NOX (ASX) Chart |